{"id":"loncastuximab-tesirine","rwe":[],"tags":[],"safety":{"boxedWarnings":["Effusion and Edema","Myelosuppression","Infections","Hepatotoxicity, including DILI","Cutaneous Reactions"],"drugInteractions":[],"commonSideEffects":[{"effect":"Thrombocytopenia","drugRate":"≥20%","severity":"Not specified"},{"effect":"Increased gamma-glutamyltransferase","drugRate":"≥20%","severity":"Not specified"},{"effect":"Neutropenia","drugRate":"≥20%","severity":"Not specified"},{"effect":"Anemia","drugRate":"≥20%","severity":"Not specified"},{"effect":"Hyperglycemia","drugRate":"≥20%","severity":"Not specified"},{"effect":"Transaminase elevation","drugRate":"≥20%","severity":"Not specified"},{"effect":"Fatigue","drugRate":"≥20%","severity":"Not specified"},{"effect":"Hypoalbuminemia","drugRate":"≥20%","severity":"Not specified"},{"effect":"Rash","drugRate":"≥20%","severity":"Not specified"},{"effect":"Edema","drugRate":"≥20%","severity":"Not specified"},{"effect":"Nausea","drugRate":"≥20%","severity":"Not specified"},{"effect":"Musculoskeletal pain","drugRate":"≥20%","severity":"Not specified"}],"contraindications":[],"specialPopulations":{}},"trials":[],"_chembl":{"chemblId":"CHEMBL4297778","moleculeType":"Antibody drug conjugate"},"aliases":[],"patents":[],"pricing":[],"offLabel":[],"timeline":[{"date":"Not provided","type":"Approval","milestone":"Accelerated approval based on overall response rate","regulator":"FDA"}],"_dailymed":{"setId":"af54af12-3edf-4301-8bc5-0446bc813c1d","title":"ZYNLONTA (LONCASTUXIMAB TESIRINE) INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [ADC THERAPEUTICS AMERICA, INC.]"},"aiSummary":"Loncastuximab tesirine (ZYNLONTA) is an antibody-drug conjugate (ADC) targeting CD19, approved for treating relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. It works by binding to CD19 on B-lineage cells, internalizing, and releasing a cytotoxic agent that induces cell death. Common side effects include thrombocytopenia, neutropenia, anemia, and fatigue. There are no contraindications, but it carries warnings for effusion, myelosuppression, infections, hepatotoxicity, and cutaneous reactions.","ecosystem":[],"mechanism":{"target":"CD19","novelty":"Loncastuximab tesirine is a novel ADC that combines a specific targeting mechanism with a potent cytotoxic payload, offering a new therapeutic option for relapsed or refractory large B-cell lymphoma.","modality":"Monoclonal Antibody and Alkylating Agent Conjugate","drugClass":"Antibody-Drug Conjugate (ADC)","explanation":"The monoclonal IgG1 kappa antibody component binds to human CD19, a transmembrane protein expressed on the surface of cells of B-lineage origin. The small molecule component, SG3199, is a PBD dimer and alkylating agent that forms highly cytotoxic DNA interstrand crosslinks upon release, leading to cell death.","oneSentence":"Loncastuximab tesirine is an ADC that targets CD19 on B-lineage cells, internalizes, and releases a cytotoxic agent to induce cell death.","technicalDetail":"Upon binding to CD19, loncastuximab tesirine is internalized and SG3199 is released via proteolytic cleavage. SG3199 binds to the DNA minor groove and forms DNA interstrand crosslinks, which are highly cytotoxic and lead to cell death."},"_scrapedAt":"2026-03-27T23:34:06.725Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"commercial":{"yoyGrowth":"Not provided","launchDate":"Not provided","annualCostUS":"Not provided","currentRevenue":"Not provided","patientPopulation":"Adult patients with relapsed or refractory large B-cell lymphoma","peakSalesEstimate":"Not provided"},"references":[],"biosimilars":[],"competitors":[],"indications":{"approved":["Relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, DLBCL arising from low-grade lymphoma, and high-grade B-cell lymphoma"],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT04384484","phase":"PHASE3","title":"Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"ADC Therapeutics S.A.","startDate":"2020-09-16","conditions":"Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma","enrollment":440},{"nctId":"NCT04998669","phase":"PHASE2","title":"Loncastuximab Tesirine in Combination With Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma","status":"RECRUITING","sponsor":"Juan P. Alderuccio, MD","startDate":"2022-02-11","conditions":"Follicular Lymphoma","enrollment":100},{"nctId":"NCT04970901","phase":"PHASE1","title":"A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)","status":"RECRUITING","sponsor":"ADC Therapeutics S.A.","startDate":"2022-06-17","conditions":"B-Cell Non-Hodgkin Lymphoma, Relapsed B-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma","enrollment":200},{"nctId":"NCT06919939","phase":"PHASE2","title":"Epcoritamab in Combination With Loncastuximab Tesirine in Relapsed/Refractory Large B-cell Lymphoma","status":"RECRUITING","sponsor":"University of Miami","startDate":"2026-01-07","conditions":"Large B-cell Lymphoma, Relapse","enrollment":26},{"nctId":"NCT05991388","phase":"PHASE2, PHASE3","title":"A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma","status":"RECRUITING","sponsor":"University of Birmingham","startDate":"2024-05-02","conditions":"B-cell Non Hodgkin Lymphoma","enrollment":210},{"nctId":"NCT05658562","phase":"PHASE1, PHASE2","title":"A Study of MT-2111 in Patients With Relapsed/Refractory DLBCL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Tanabe Pharma Corporation","startDate":"2023-01-30","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":46},{"nctId":"NCT05053659","phase":"PHASE1","title":"Loncastuximab Tesirine and Venetoclax for Relapsed/ Refractory Non-Hodgkin Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Paolo Caimi, MD","startDate":"2022-06-20","conditions":"Relapsed Non Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma","enrollment":23},{"nctId":"NCT05464719","phase":"PHASE2","title":"A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2022-09-23","conditions":"Large B-cell Lymphoma, Lymphoma","enrollment":30},{"nctId":"NCT05249959","phase":"PHASE2","title":"Consolidation With Loncastuximab Tesirine After a Short Course of Immunochemotherapy in BTKi-treated (or Intolerant) Relapsed/Refractory Mantle Cell Lymphoma Patients.","status":"RECRUITING","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2022-03-21","conditions":"Relapsed Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma","enrollment":49},{"nctId":"NCT06607549","phase":"PHASE1","title":"Loncastuximab Tesirine and Rituximab Following Stereotactic Radiosurgery in Patients With Central Nervous System Lymphomas (SOLAR)","status":"RECRUITING","sponsor":"University of Utah","startDate":"2025-03-18","conditions":"Central Nervous System Lymphoma","enrollment":12},{"nctId":"NCT06788964","phase":"PHASE2","title":"Loncastuximab Tesirine and Rituximab as Bridging Therapy Before Standard-of-care CAR-T Therapy in Patients With Large B-cell Lymphoma (CORAL)","status":"RECRUITING","sponsor":"University of Utah","startDate":"2025-08-25","conditions":"Relapsed or Refractory Large B-cell Lymphoma","enrollment":29},{"nctId":"NCT05600686","phase":"PHASE2","title":"Loncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Diffuse Large B-cell Lymphoma","status":"RECRUITING","sponsor":"Joseph Tuscano","startDate":"2023-05-24","conditions":"Double-Expressor Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements","enrollment":24},{"nctId":"NCT05453396","phase":"PHASE2","title":"Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies","status":"RECRUITING","sponsor":"University of Washington","startDate":"2023-08-07","conditions":"Post-Transplant Lymphoproliferative Disorder, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma","enrollment":40},{"nctId":"NCT05270057","phase":"PHASE1","title":"Loncastuximab Tesirine in Combination With DA-EPOCH-R in Patients With Previously Untreated Aggressive B-cell Lymphoid Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2023-01-26","conditions":"B-cell Lymphoma, Burkitt Lymphoma","enrollment":11},{"nctId":"NCT05672251","phase":"PHASE2","title":"Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2024-01-02","conditions":"Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Grade 3b Follicular Lymphoma, Recurrent High Grade B-Cell Lymphoma","enrollment":36},{"nctId":"NCT05971251","phase":"PHASE1","title":"Addition of Loncastuximab Tesirine to Acalbrutinib , Chronic Lymphocytic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2023-12-18","conditions":"Chronic Lymphocytic Leukemia","enrollment":24},{"nctId":"NCT05296070","phase":"PHASE2","title":"Open-label of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Marginal Zone Lymphoma","status":"RECRUITING","sponsor":"University of Miami","startDate":"2022-06-21","conditions":"Marginal Zone Lymphoma","enrollment":50},{"nctId":"NCT07197307","phase":"PHASE2","title":"Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)","status":"NOT_YET_RECRUITING","sponsor":"Universität Münster","startDate":"2025-10-15","conditions":"Aggressive Diffuse Large B-cell Lymphoma, High-grade B-cell Lymphoma (HGBL), Follicular Lymphoma (FL) Grade 3B","enrollment":120},{"nctId":"NCT06977711","phase":"PHASE1","title":"Loncastuximab and Roflumilast Added to R-CHOP (Lo-(Rituximab and Roflumilast) RR-CHOP) for Naïve High-Risk Diffuse Large B-cell Lymphoma (DLBCL)","status":"RECRUITING","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2025-06-20","conditions":"Diffuse Large B-cell Lymphoma","enrollment":10},{"nctId":"NCT05660395","phase":"PHASE1","title":"A Study to Evaluate the Pharmacokinetics and Safety of Loncastuximab Tesirine in Participants With Relapsed or Refractory Diffuse Large B-cell Lymphoma or High-grade B-cell Lymphoma With Hepatic Impairment (LOTIS-10)","status":"RECRUITING","sponsor":"ADC Therapeutics S.A.","startDate":"2023-08-28","conditions":"Diffuse Large B-Cell Lymphoma, High-grade B-cell Lymphoma","enrollment":56},{"nctId":"NCT05190705","phase":"PHASE2","title":"Loncastuximab Tesirine in WM","status":"RECRUITING","sponsor":"Shayna Sarosiek, MD","startDate":"2022-02-17","conditions":"Waldenstrom Macroglobulinemia","enrollment":36},{"nctId":"NCT06918912","phase":"PHASE2","title":"Study of Loncastuximab Tesirine in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) or High-Grade B-Cell Lymphoma (HGBCL) Following CAR-T Therapy Failure","status":"RECRUITING","sponsor":"Istituto Clinico Humanitas","startDate":"2023-06-16","conditions":"Diffuse Large B-Cell Lymphoma, High-grade B-cell Lymphoma (HGBCL), B-Cell Lymphoma Treatment","enrollment":50},{"nctId":"NCT05144009","phase":"PHASE2","title":"A Study of Loncastuximab Tesirine and Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Participants With Diffuse Large B-cell Lymphoma (DLBCL)","status":"TERMINATED","sponsor":"ADC Therapeutics S.A.","startDate":"2022-06-21","conditions":"Diffuse Large B-cell Lymphoma","enrollment":41},{"nctId":"NCT04082936","phase":"PHASE1, PHASE2","title":"A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma","status":"TERMINATED","sponsor":"IGM Biosciences, Inc.","startDate":"2019-09-30","conditions":"Non-Hodgkin Lymphoma, Follicular Lymphoma, DLBCL","enrollment":97},{"nctId":"NCT03684694","phase":"PHASE1, PHASE2","title":"Safety and Efficacy Study of Loncastuximab Tesirine + Ibrutinib in Diffuse Large B-Cell or Mantle Cell Lymphoma","status":"TERMINATED","sponsor":"ADC Therapeutics S.A.","startDate":"2018-12-01","conditions":"Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma","enrollment":136},{"nctId":"NCT05222438","phase":"PHASE2","title":"Trial of Loncastuximab Tesirine in High Risk Diffuse Large B-cell Lymphoma Post Transplant","status":"WITHDRAWN","sponsor":"Barbara Ann Karmanos Cancer Institute","startDate":"2022-04-08","conditions":"Relapsed Diffuse Large B-cell Lymphoma","enrollment":""},{"nctId":"NCT04699461","phase":"PHASE2","title":"Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine Versus Idelalisib in Participants With Relapsed or Refractory Follicular Lymphoma","status":"TERMINATED","sponsor":"ADC Therapeutics S.A.","startDate":"2021-11-04","conditions":"Relapsed Follicular Lymphoma, Refractory Follicular Lymphoma","enrollment":6},{"nctId":"NCT03589469","phase":"PHASE2","title":"Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma","status":"COMPLETED","sponsor":"ADC Therapeutics S.A.","startDate":"2018-08-01","conditions":"Diffuse Large B-Cell Lymphoma Refractory, Diffuse Large B-cell Lymphoma Recurrent","enrollment":145},{"nctId":"NCT05228249","phase":"PHASE1","title":"Loncastuximab Tesirine in Combination With Chemotherapy Prior to Stem Cell Transplant for the Treatment of Recurrent or Refractory Diffuse Large B-Cell Lymphoma","status":"WITHDRAWN","sponsor":"Fred Hutchinson Cancer Center","startDate":"2023-04","conditions":"Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements","enrollment":""},{"nctId":"NCT05349383","phase":"","title":"Evaluation of Reporting of Antibody-Drug Conjugate Associated Sepsis-related Toxicities","status":"COMPLETED","sponsor":"Central South University","startDate":"2022-04-22","conditions":"Sepsis (SMQ), Opportunistic Infections, Agranulocytosis","enrollment":24618},{"nctId":"NCT05160064","phase":"","title":"Long-term Registry of Patients Treated With Loncastuximab Tesirine","status":"WITHDRAWN","sponsor":"ADC Therapeutics S.A.","startDate":"2022-06-30","conditions":"B-Cell Lymphomas","enrollment":""},{"nctId":"NCT04974996","phase":"PHASE1","title":"A Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Antitumor Activity of Loncastuximab Tesirine in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated Diffuse Large B-cell Lymphoma (LOTIS-8)","status":"WITHDRAWN","sponsor":"ADC Therapeutics S.A.","startDate":"2022-02-01","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":""},{"nctId":"NCT03685344","phase":"PHASE1","title":"Safety and Antitumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular Lymphoma","status":"TERMINATED","sponsor":"ADC Therapeutics S.A.","startDate":"2019-02-04","conditions":"Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma","enrollment":13},{"nctId":"NCT02669264","phase":"PHASE1","title":"Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)","status":"TERMINATED","sponsor":"ADC Therapeutics S.A.","startDate":"2016-03","conditions":"Acute Lymphoblastic Leukemia","enrollment":35},{"nctId":"NCT02669017","phase":"PHASE1","title":"Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL)","status":"COMPLETED","sponsor":"ADC Therapeutics S.A.","startDate":"2016-03","conditions":"Non-Hodgkin Lymphoma, Burkitt's Lymphoma, Chronic Lymphocytic Leukemia","enrollment":183},{"nctId":"NCT04705454","phase":"","title":"Loncastixumab Tesirine (ADCT-402) Expanded Access Program (EAP) for Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma","status":"NO_LONGER_AVAILABLE","sponsor":"ADC Therapeutics S.A.","startDate":"","conditions":"Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)","enrollment":""}],"_emaApprovals":[],"_faersSignals":[{"count":17,"reaction":"DISEASE PROGRESSION"},{"count":9,"reaction":"PNEUMONIA"},{"count":8,"reaction":"THROMBOCYTOPENIA"},{"count":7,"reaction":"ANAEMIA"},{"count":7,"reaction":"PLATELET COUNT DECREASED"},{"count":6,"reaction":"CNS VENTRICULITIS"},{"count":6,"reaction":"COVID-19"},{"count":6,"reaction":"DEATH"},{"count":6,"reaction":"DRUG INEFFECTIVE"},{"count":6,"reaction":"GAMMA-GLUTAMYLTRANSFERASE INCREASED"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"formularyStatus":[],"_approvalHistory":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":95,"therapeuticAreas":["Oncology"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"marketed","status":"approved","brandName":"LONCASTUXIMAB TESIRINE","genericName":"LONCASTUXIMAB TESIRINE","companyName":"","companyId":"","modality":"Antibody drug conjugate","firstApprovalDate":"2021","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2026-02-20T00:00:00.000Z","mah":"ADC Therapeutics SA","brand_name_local":null,"application_number":"BLA761196"},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"AU","regulator":"TGA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Zynlonta","application_number":null},{"country_code":"CH","regulator":"Swissmedic","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Zynlonta","application_number":null},{"country_code":"NO","regulator":"NoMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Zynlonta","application_number":null},{"country_code":"IS","regulator":"IMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Zynlonta","application_number":null},{"country_code":"NZ","regulator":"Medsafe","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Zynlonta","application_number":null},{"country_code":"AT","regulator":"AGES","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Zynlonta","application_number":null},{"country_code":"BE","regulator":"FAMHP","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Zynlonta","application_number":null},{"country_code":"EU","regulator":"EMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Zynlonta","application_number":"EMEA/H/C/005685"},{"country_code":"GB","regulator":"MHRA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Zynlonta","application_number":null},{"country_code":"BG","regulator":"BDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Zynlonta","application_number":null},{"country_code":"HR","regulator":"HALMED","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Zynlonta","application_number":null},{"country_code":"CY","regulator":"PHS","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Zynlonta","application_number":null},{"country_code":"CZ","regulator":"SUKL","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Zynlonta","application_number":null},{"country_code":"DK","regulator":"DKMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Zynlonta","application_number":null},{"country_code":"EE","regulator":"SAM","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Zynlonta","application_number":null},{"country_code":"FI","regulator":"Fimea","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Zynlonta","application_number":null},{"country_code":"FR","regulator":"ANSM","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Zynlonta","application_number":null},{"country_code":"DE","regulator":"BfArM","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Zynlonta","application_number":null},{"country_code":"GR","regulator":"EOF","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Zynlonta","application_number":null},{"country_code":"HU","regulator":"OGYEI","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Zynlonta","application_number":null},{"country_code":"IE","regulator":"HPRA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Zynlonta","application_number":null},{"country_code":"IT","regulator":"AIFA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Zynlonta","application_number":null},{"country_code":"LV","regulator":"ZVA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Zynlonta","application_number":null},{"country_code":"LT","regulator":"VVKT","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Zynlonta","application_number":null},{"country_code":"LU","regulator":"MS","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Zynlonta","application_number":null},{"country_code":"MT","regulator":"MMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Zynlonta","application_number":null},{"country_code":"NL","regulator":"MEB","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Zynlonta","application_number":null},{"country_code":"PL","regulator":"URPL","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Zynlonta","application_number":null},{"country_code":"PT","regulator":"Infarmed","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Zynlonta","application_number":null},{"country_code":"RO","regulator":"ANMDMR","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Zynlonta","application_number":null},{"country_code":"SK","regulator":"SIDC","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Zynlonta","application_number":null},{"country_code":"SI","regulator":"JAZMP","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Zynlonta","application_number":null},{"country_code":"ES","regulator":"AEMPS","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Zynlonta","application_number":null},{"country_code":"SE","regulator":"MPA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Zynlonta","application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":10,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}